

# Thierry Landre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7644286/publications.pdf>

Version: 2024-02-01

12  
papers

203  
citations

1163117

8  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 719-726.	4.2	33
2	Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1553.	3.7	7
3	Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. <i>Cancers</i> , 2021, 13, 6035.	3.7	6
4	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or PD-L1-expressing metastatic non-small-cell lung cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 441-448.	2.5	8
5	Immune Checkpoint Inhibitors for Patients Aged 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. <i>Drugs and Aging</i> , 2020, 37, 747-754.	2.7	24
6	First-line immune-checkpoint inhibitor plus chemotherapy <i>versus</i> chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097713.	3.2	14
7	First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3333-3339.	2.5	20
8	Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e806-e813.	1.9	5
9	Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1125-1130.	2.2	16
10	Chronological Age and Risk of Chemotherapy Nonfeasibility: <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 73-80.	1.3	15
11	Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3070-3070.	1.6	23
12	Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1305-1310.	2.2	30